Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse
Open Access
- 2 April 2022
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (3) , 1159-1174
Abstract
Purpose: Based on the tumor-promoting features of extracellular vesicles (EV) and PD-L1/2-bearing EV subpopulations (PD-L1/2EV), we evaluated their potential as surrogate markers for disease progression or eligibility criteria for PD-1 immune checkpoint inhibition (ICI) approaches in early triple-negative breast cancer (TNBC). Methods: After enrichment of EV from plasma samples of 56 patients before and 50 after chemotherapy (CT), we determined levels of EV particle number and PD-L1/2EV by nanoparticle tracking analysis or ELISA and associated the results with clinical status/outcome and the presence of distinct circulating tumor cells (CTC) subpopulations. Results: Compared to healthy controls, patients had a tenfold higher EV concentration and significantly elevated PD L2EV but not PD L1EV levels. The most important clinical implications were found for PD-L2EV. High PD-L2EV levels were associated with a significantly reduced 3-year progression-free and overall survival (PFS and OS). A loss of PD-L2EV after CT was significantly more prominent in patients achieving pathological complete response (pCR). Increased pre-CT PD-L2EV levels were found in patients having NOTCH1-positive or ERBB3-positive CTC. The presence of ERBB3-positive CTC combined with high pre-CT PD-L2EV resulted in a shorter PFS. Conclusion: This study highlights PD L2EV as a promising biomarker for risk assessment of TNBC patients and represents the basic for additional studies introducing PD-L2EV as an eligibility criterion for PD-1 ICI approaches.Keywords
Funding Information
- Universitätsklinikum Essen
This publication has 59 references indexed in Scilit:
- Frequent expression of PD‐L1 on circulating breast cancer cellsMolecular Oncology, 2015
- Biological properties of extracellular vesicles and their physiological functionsJournal of Extracellular Vesicles, 2015
- Elevated Concentration of Microvesicles Isolated from Peripheral Blood in Breast Cancer PatientsArchives of Medical Research, 2013
- Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopyColloids and Surfaces B: Biointerfaces, 2011
- Membrane vesicles, current state-of-the-art: emerging role of extracellular vesiclesCellular and Molecular Life Sciences, 2011
- The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeuticsSeminars in Cell & Developmental Biology, 2010
- Triple-Negative Breast CancerThe Cancer Journal, 2010
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Downregulation of erbB3 abrogates erbB2‐mediated tamoxifen resistance in breast cancer cellsInternational Journal of Cancer, 2007
- Histologische Regression des Mammakarzinoms nach primärer (neoadjuvanter) ChemotherapieGeburtshilfe und Frauenheilkunde, 1994